Working with Transgenomic, a US based Life Science company and the Universities of Nebraska and Thessaly, Biosignatures analysed 234 neuro-degenerative samples (for Alzheimer's disease and Parkinson's disease) within two weeks.

The results generated tests with impressive blind sensitivities and specificities of 90/90 and 90/80 respectively. The Parkinson's results were presented at the World Parkinson's Congress, Glasgow UK September 2010.

Results